

Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)

Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value.

Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fisher Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region.

Bronwyn Brophy will join the company at the latest on 1 August 2023.

As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, today Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.

Jón Sigurdsson, chairman of the board, says: "I am very pleased that we have been able to assign Bronwyn Brophy as CEO. She has an extensive experience of developing businesses and has a wide international experience which is important for Vitrolife. Again, I would like to thank Thomas Axelsson for an excellent job done for Vitrolife and for our great cooperation."

Bronwyn Brophy comments the appointment: "I am very honored to the appointment as new CEO of Vitrolife. I believe the company has a very exciting future with great growth potential with strong distributors and global partners".

For further information, please contact:

Thomas Axelsson, CEO, phone: +46 31 721 80 01

Patrik Tolf, CFO, phone: +46 31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.15 CET on February 1, 2023.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.